U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt

Exelixis

Market Cap: US$14.5b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

ADMA Biologics

Market Cap: US$2.0b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

MeiraGTx Holdings

Market Cap: US$1.3b

A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.

CorMedix

Market Cap: US$607.2m

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

Q32 Bio

Market Cap: US$323.3m

A clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.

Compugen

Market Cap: US$233.0m

A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

Vaxart

Market Cap: US$121.6m

A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.

Rallybio

Market Cap: US$91.1m

A clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.

Actinium Pharmaceuticals

Market Cap: US$37.4m

Develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.